Platelet and coagulation hemostasis status in patients with atrial fibrillation depending on warfarin dosing method
DOI:
https://doi.org/10.14739/2310-1210.2022.6.263895Keywords:
atrial fibrillation, warfarin, platelet aggregation, D-dimer, genotype-guided dosingAbstract
The aim. To evaluate indicators of induced platelet aggregation and D-dimer level in patients with atrial fibrillation (AF) depending on the method of warfarin (WF) dosing.
Materials and methods. The study involved 110 patients with AF (mean age 68.72 ± 0.79; men – 57, women – 53). Patients with AF were divided into two groups: the main group – 50 patients with AF and genotype-guided dosing method, the control group – 60 patients with AF and traditional dosing method. CYP2C9, CYP4F2, VKORC1 genetic polymorphisms were determined using multiplex real time polymerase chain reaction, D-dimer concentration – by the method of solid-phase enzyme immunoassay; ADP- and epinephrine-induced aggregation indicators – by the method of G. Born.
Results. The percentage (by 24 %), time (by 3 min 6 s) and rate in 30 s (by 19.5 %/min) of ADP-induced platelet aggregation were significantly lower in patients with AF and genotype-guided WF dosing method. D-dimer concentration in patients of the main and control groups did not differ significantly. However, significantly fewer patients with elevated D-dimer values were registered in the group with genotype-guided WF dosing method compared to the group with traditional dosing method: 0 (0.00 %) vs. 7 (11.67 %) at 500 ng FEU/ml cut-off (χ2 = 4.43, P < 0.05), 1 (2.00 %) vs. 9 (15.00 %) at 390 ng FEU/ml cut-off (χ2 = 4.16, P < 0.05), 0 (0.00 %) vs. 7 (11.67 %) at age-adjusted cut-off (χ2 = 4.43, P < 0.05).
Conclusions. The obtained results may indicate a potentially lower risk of thrombotic events in patients with AF and genotype-guided WF dosing method compared to the group with traditional dosing method, which confirms the benefit of the widespread use of the pharmacogenetic testing in clinical practice.
References
Ding, W. Y., Gupta, D., & Lip, G. (2020). Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020. Heart (British Cardiac Society), 106(19), 1463-1468. https://doi.org/10.1136/heartjnl-2020-316977
Kosiuk, J., Uhe, T., Stegmann, C., Ueberham, L., Bertagnolli, L., Dagres, N., Dinov, B., Müssigbrodt, A., Richter, S., Paetsch, I., Jahnke, C., Hilbert, S., Sommer, P., Hindricks, G., & Bollmann, A. (2019). Morphological determinators of platelet activation status in patients with atrial fibrillation. International journal of cardiology, 279, 90-95. https://doi.org/10.1016/j.ijcard.2018.11.096
Willoughby, S. R., Roberts-Thomson, R. L., Lim, H. S., Schultz, C., Prabhu, A., De Sciscio, P., Wong, C. X., Worthley, M. I., & Sanders, P. (2010). Atrial platelet reactivity in patients with atrial fibrillation. Heart rhythm, 7(9), 1178-1183. https://doi.org/10.1016/j.hrthm.2010.01.042
Gosk-Bierska, I., Wasilewska, M., & Wysokiński, W. (2016). Role of Platelets in Thromboembolism in Patients with Atrial Fibrillation. Advances in clinical and experimental medicine, 25(1), 163-171. https://doi.org/10.17219/acem/38544
Procter, N. E., Ball, J., Ngo, D. T., Chirkov, Y. Y., Isenberg, J. S., Hylek, E. M., Stewart, S., & Horowitz, J. D. (2016). Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieu. Herz, 41(1), 57-62. https://doi.org/10.1007/s00059-015-4335-y
Choi, J. H., Cha, J. K., & Huh, J. T. (2014). Adenosine diphosphate-induced platelet aggregation might contribute to poor outcomes in atrial fibrillation-related ischemic stroke. Journal of stroke and cerebrovascular, 23(3), e215-e220. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.10.011
Weitz, J. I., Fredenburgh, J. C., & Eikelboom, J. W. (2017). A Test in Context: D-Dimer. Journal of the American College of Cardiology, 70(19), 2411-2420. https://doi.org/10.1016/j.jacc.2017.09.024
Siegbahn, A., Oldgren, J., Andersson, U., Ezekowitz, M. D., Reilly, P. A., Connolly, S. J., Yusuf, S., Wallentin, L., & Eikelboom, J. W. (2016). D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thrombosis and haemostasis, 115(5), 921-930. https://doi.org/10.1160/TH15-07-0529
Christersson, C., Wallentin, L., Andersson, U., Alexander, J. H., Ansell, J., De Caterina, R., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J. D., Huber, K., Husted, S., Hylek, E. M., Lopes, R. D., & Siegbahn, A. (2014). D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. Journal of thrombosis and haemostasis : JTH, 12(9), 1401-1412. https://doi.org/10.1111/jth.12638
Ruff, C. T., Giugliano, R. P., Braunwald, E., Murphy, S. A., Brown, K., Jarolim, P., Mercuri, M., Antman, E. M., & Morrow, D. A. (2016). Cardiovascular Biomarker Score and Clinical Outcomes in Patients with Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA cardiology, 1(9), 999-1006. https://doi.org/10.1001/jamacardio.2016.3311
Douma, R. A., le Gal, G., Söhne, M., Righini, M., Kamphuisen, P. W., Perrier, A., Kruip, M. J., Bounameaux, H., Büller, H. R., & Roy, P. M. (2010). Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ (Clinical research ed.), 340, c1475. https://doi.org/10.1136/bmj.c1475
Almorad, A., Ohanyan, A., Pintea Bentea, G., Wielandts, J. Y., El Haddad, M., Lycke, M., O'Neill, L., Morissens, M., De Keyzer, E., Nguyen, T., Anghel, L., Samyn, S., Berdaoui, B., Tavernier, R., Vandekerckhove, Y., Duytschaever, M., Verbeet, T., Knecht, S., & Castro Rodriguez, J. (2021). D-dimer blood concentrations to exclude left atrial thrombus in patients with atrial fibrillation. Heart (British Cardiac Society), 107(3), 195-200. https://doi.org/10.1136/heartjnl-2020-317612
Du, X., & Wang, Y. (2019). The diagnostic efficacy of cardiac CTA combined with D-dimer assay for the detection of left atrial thrombus in patients with atrial fibrillation. The American journal of emergency medicine, 37(10), 1922-1926. https://doi.org/10.1016/j.ajem.2019.01.014
Diaz-Arocutipa, C., Gonzales-Luna, A. C., Brañez-Condorena, A., & Hernandez, A. V. (2021). Diagnostic accuracy of D-dimer to detect left atrial thrombus in patients with atrial fibrillation: A systematic review and meta-analysis. Heart rhythm, 18(12), 2128-2136. https://doi.org/10.1016/j.hrthm.2021.08.027
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G. A., Dilaveris, P. E., Fauchier, L., Filippatos, G., Kalman, J. M., La Meir, M., Lane, D. A., Lebeau, J. P., Lettino, M., Lip, G., Pinto, F. J., Thomas, G. N., … ESC Scientific Document Group (2021). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European heart journal, 42(5), 373-498. https://doi.org/10.1093/eurheartj/ehaa612
Gage, B. F., Eby, C., Johnson, J. A., Deych, E., Rieder, M. J., Ridker, P. M., Milligan, P. E., Grice, G., Lenzini, P., Rettie, A. E., Aquilante, C. L., Grosso, L., Marsh, S., Langaee, T., Farnett, L. E., Voora, D., Veenstra, D. L., Glynn, R. J., Barrett, A., & McLeod, H. L. (2008). Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical pharmacology and therapeutics, 84(3), 326-331. https://doi.org/10.1038/clpt.2008.10
Heneghan, C., Tyndel, S., Bankhead, C., Wan, Y., Keeling, D., Perera, R., & Ward, A. (2010). Optimal loading dose for the initiation of warfarin: a systematic review. BMC cardiovascular disorders, 10, 18. https://doi.org/10.1186/1471-2261-10-18
Kolesnyk, M. Yu., & Mykhailovskyi, Ya. M. (2021). Frequencies of polymorphisms in genes affecting the pharmacokinetics of warfarin in the Zaporizhzhia region. Zaporozhye medical journal, 23(4), 476-479. https://doi.org/10.14739/2310-1210.2021.4.227002
Kolesnyk, M. Yu., & Mykhailovskyi, Ya. M. (2022). Efektyvnist i bezpechnist terapii warfarynom u khvorykh iz fibryliatsiieiu peredserd pid chas vyznachennia dozy farmakohenetychnym metodom [Efficacy and safety of warfarin therapy in patients with atrial fibrillation using genotype-guided dosing method]. Zaporozhye medical journal, 24(4), 390-395. [in Ukrainian]. https://doi.org/10.14739/2310-1210.2022.4.256945
Nehaj, F., Sokol, J., Ivankova, J., Mokan, M., Mokan, M., & Stasko, J. (2020). Edoxaban affects TRAP-dependent platelet aggregation. Journal of thrombosis and thrombolysis, 49(4), 578-583. https://doi.org/10.1007/s11239-020-02093-9
Bánovčin, P., Jr, Škorňová, I., Samoš, M., Schnierer, M., Bolek, T., Kovář, F., Staško, J., Kubisz, P., & Mokáň, M. (2017). Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients with Atrial Fibrillation: A Pilot Study. Journal of cardiovascular pharmacology, 70(4), 263-266. https://doi.org/10.1097/FJC.0000000000000516
Ferreira, C. N., Vieira, L. M., Dusse, L. M., Reis, C. V., Amaral, C. F., Esteves, W. A., Fenelon, L. M., & Carvalho, M. G. (2002). Evaluation of the blood coagulation mechanism and platelet aggregation in individuals with mechanical or biological heart prostheses. Blood coagulation & fibrinolysis, 13(2), 129-134. https://doi.org/10.1097/00001721-200203000-00008
Mieszczak, C., & Winther, K. (1996). Does warfarin enhance platelet activity?. Thrombosis research, 84(4), 285-287. https://doi.org/10.1016/s0049-3848(96)00188-0
Chylova, M., Motovska, Z., Fialova, A., Stetkarova, I., Peisker, T., & Kalvach, P. (2021). The effect of warfarin administration on platelet aggregation. Bratislavske lekarske listy, 122(5), 320-324. https://doi.org/10.4149/BLL_2021_054
S Markus H. (2020). D-dimer in ischemic stroke, and insights from HEADPOST into swallowing problems and outcome after stroke. International journal of stroke, 15(2), 121. https://doi.org/10.1177/1747493020906727
Ibebuogu, U. N., Schafer, J. H., Schwade, M. J., Waller, J. L., Sharma, G. K., & Robinson, V. (2020). Useful indices of thrombogenesis in the exclusion of intra-cardiac thrombus. Echocardiography, 37(1), 86-95. https://doi.org/10.1111/echo.14562
Xu, Y., Wang, B., Jiang, L. J., Lu, X. P., Zhao, X. Y., & Wang, F. (2019). Roles of Microembolus and Plasma D-dimer in Evaluating the Warfarin Anticoagulant Therapy Efficacies for Patients with Atrial Fibrillation. The heart surgery forum, 22(1), E015-E018. https://doi.org/10.1532/hsf.2197
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
